Posted on

National ADHD Awareness Month – October 2019

Posted on

  Undiagnosed, untreated attention-deficit/hyperactivity disorder (ADHD) can wreak havoc on your life, and it can also impact your loved ones. Each year, we recognize ADHD Awareness Month in October as a time to celebrate the progress made in ADHD education and advocacy, understand the work that still needs to be done, and raise awareness about…

Read more

Posted on

Breast Cancer Drugs May Severely Inflame Lungs, FDA Warns

Posted on

The US Food and Drug Administration (FDA) issued a warning today that the commonly prescribed breast cancer therapies known as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors may cause rare but severe inflammation of the lungs. The related products include palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Eli Lilly), which are approved for use in patients with hormone receptor (HR)-positive, human epidermal…

Read more

Posted on

FDA OKs Istradefylline for Parkinson’s Disease ‘Off’ Episodes

Posted on

The US Food and Drug Administration (FDA) has approved istradefylline (Nourianz, Kyowa Kirin) tablets as add-on treatment to levodopa/carbidopa in adults with Parkinson’s disease (PD) experiencing “off” episodes. Istradefylline is a selective adenosine A2A receptor antagonist. Its effectiveness in treating “off” episodes in patients with PD taking levodopa/carbidopa was shown in four 12-week, placebo-controlled clinical studies that included a total of 1143 participants.…

Read more